Literature DB >> 22279419

MicroRNA alterations in Barrett's esophagus, esophageal adenocarcinoma, and esophageal adenocarcinoma cell lines following cranberry extract treatment: Insights for chemoprevention.

Laura A Kresty1, Jennifer Clarke, Kristin Ezell, Amy Exum, Amy B Howell, Toumy Guettouche.   

Abstract

BACKGROUND: Aberrant expression of small noncoding endogenous RNA molecules known as microRNAs (miRNAs) is documented to occur in multiple cancer types including esophageal adencarcinoma (EAC) and its only known precursor, Barrett's esophagus (BE). Recent studies have linked dysregulation of specific miRNAs to histological grade, neoplastic progression and metastatic potential.
MATERIALS AND METHODS: Herein, we present a summary of previously reported dysregulated miRNAs in BE and EAC tissues as well as EAC cell lines and evaluate a cranberry proanthocyanidin rich extract's (C-PAC) ability to modulate miRNA expression patterns of three human EAC cell lines (JHEso-Ad-1, OE33 and OE19).
RESULTS: A review of 13 published studies revealed dysregulation of 87 miRNAs in BE and EAC tissues, whereas 52 miRNAs have been reported to be altered in BE or EAC cell lines, with 48% overlap with miRNA changes reported in tissues. We report for the first time C-PAC-induced modulation of five miRNAs in three EAC cell lines resulting in 26 validated gene targets and identification of key signaling pathways including p53, angiogenesis, T-cell activation and apoptosis. Additionally, mutiple cancer related networks were ideintified as modulated by C-PAC utilizing Kyoto Encyclopedia of Genes and Genomes (KEGG), Protein Analysis Through Evolutionary Relationships (PANTHER), and MetaCore analysis tools.
CONCLUSIONS: Study results support the cancer inhibitory potential of C-PAC is in part attributable to C-PAC's ability to modify miRNA profiles within EAC cells. A number of C-PAC-modulated miRNAs have been been identified as dysregulated in BE and EAC. Further insights into miRNA dysregulation and modulation by select cancer preventive agents will support improved targeted interventions in high-risk cohorts.

Entities:  

Keywords:  Barrett's esophagus; JHAD1; OE19; OE33; chemoprevention; cranberry; esophageal adenocarcinoma; microRNA; polyphenols; proanthocyanidins

Year:  2011        PMID: 22279419      PMCID: PMC3263009          DOI: 10.4103/1477-3163.91110

Source DB:  PubMed          Journal:  J Carcinog        ISSN: 1477-3163


  56 in total

1.  A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity.

Authors:  Amy B Howell; Jess D Reed; Christian G Krueger; Ranee Winterbottom; David G Cunningham; Marge Leahy
Journal:  Phytochemistry       Date:  2005-09       Impact factor: 4.072

2.  mRNA and microRNA quality control for RT-qPCR analysis.

Authors:  C Becker; A Hammerle-Fickinger; I Riedmaier; M W Pfaffl
Journal:  Methods       Date:  2010-01-15       Impact factor: 3.608

Review 3.  MicroRNA history: discovery, recent applications, and next frontiers.

Authors:  Maria I Almeida; Rui M Reis; George A Calin
Journal:  Mutat Res       Date:  2011-03-30       Impact factor: 2.433

Review 4.  Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.

Authors:  Gary J Kelloff; Scott M Lippman; Andrew J Dannenberg; Caroline C Sigman; Homer L Pearce; Brian J Reid; Eva Szabo; V Craig Jordan; Margaret R Spitz; Gordon B Mills; Vali A Papadimitrakopoulou; Reuben Lotan; Bharat B Aggarwal; Robert S Bresalier; Jeri Kim; Banu Arun; Karen H Lu; Melanie E Thomas; Helen E Rhodes; Molly A Brewer; Michele Follen; Dong M Shin; Howard L Parnes; Jill M Siegfried; Alison A Evans; William J Blot; Wong-Ho Chow; Patricia L Blount; Carlo C Maley; Kenneth K Wang; Stephen Lam; J Jack Lee; Steven M Dubinett; Paul F Engstrom; Frank L Meyskens; Joyce O'Shaughnessy; Ernest T Hawk; Bernard Levin; William G Nelson; Waun Ki Hong
Journal:  Clin Cancer Res       Date:  2006-06-15       Impact factor: 12.531

Review 5.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.

Authors:  William C S Cho
Journal:  Int J Biochem Cell Biol       Date:  2009-12-22       Impact factor: 5.085

6.  Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.

Authors:  A A Botterweck; L J Schouten; A Volovics; E Dorant; P A van Den Brandt
Journal:  Int J Epidemiol       Date:  2000-08       Impact factor: 7.196

7.  MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma.

Authors:  B P L Wijnhoven; D J Hussey; D I Watson; A Tsykin; C M Smith; M Z Michael
Journal:  Br J Surg       Date:  2010-06       Impact factor: 6.939

8.  MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.

Authors:  Dipen M Maru; Rajesh R Singh; Christina Hannah; Constance T Albarracin; Yong X Li; Ronald Abraham; Angela M Romans; Hui Yao; Madan G Luthra; Sharmila Anandasabapathy; Stephen G Swisher; Wayne L Hofstetter; Asif Rashid; Rajyalakshmi Luthra
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

9.  Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006.

Authors:  D A Corley; A Kubo; T R Levin; G Block; L Habel; G Rumore; C Quesenberry; P Buffler
Journal:  Gut       Date:  2008-10-31       Impact factor: 23.059

10.  Screening of foods containing proanthocyanidins and their structural characterization using LC-MS/MS and thiolytic degradation.

Authors:  Liwei Gu; Mark A Kelm; John F Hammerstone; Gary Beecher; Joanne Holden; David Haytowitz; Ronald L Prior
Journal:  J Agric Food Chem       Date:  2003-12-03       Impact factor: 5.279

View more
  7 in total

1.  Upper esophageal and pharyngeal cancers.

Authors:  Jonathan M Bock; Amy B Howell; Nikki Johnston; Laura A Kresty; Daniel Lew
Journal:  Ann N Y Acad Sci       Date:  2014-09       Impact factor: 5.691

2.  Expression, modulation, and clinical correlates of the autophagy protein Beclin-1 in esophageal adenocarcinoma.

Authors:  Katherine M Weh; Amy B Howell; Laura A Kresty
Journal:  Mol Carcinog       Date:  2015-11-19       Impact factor: 4.784

3.  Cranberry proanthocyanidins inhibit esophageal adenocarcinoma in vitro and in vivo through pleiotropic cell death induction and PI3K/AKT/mTOR inactivation.

Authors:  Laura A Kresty; Katherine M Weh; Bree Zeyzus-Johns; Laura N Perez; Amy B Howell
Journal:  Oncotarget       Date:  2015-10-20

Review 4.  Targeting MicroRNA in Cancer Using Plant-Based Proanthocyanidins.

Authors:  Rishipal R Bansode; Janak R Khatiwada; Jack N Losso; Leonard L Williams
Journal:  Diseases       Date:  2016-04-28

5.  Cranberry proanthocyanidins modulate reactive oxygen species in Barrett's and esophageal adenocarcinoma cell lines.

Authors:  Katherine M Weh; Harini S Aiyer; Amy B Howell; Laura A Kresty
Journal:  J Berry Res       Date:  2016       Impact factor: 2.352

6.  Cranberry Polyphenols in Esophageal Cancer Inhibition: New Insights.

Authors:  Katherine M Weh; Yun Zhang; Connor L Howard; Amy B Howell; Jennifer L Clarke; Laura A Kresty
Journal:  Nutrients       Date:  2022-02-24       Impact factor: 5.717

Review 7.  Cranberries and Cancer: An Update of Preclinical Studies Evaluating the Cancer Inhibitory Potential of Cranberry and Cranberry Derived Constituents.

Authors:  Katherine M Weh; Jennifer Clarke; Laura A Kresty
Journal:  Antioxidants (Basel)       Date:  2016-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.